-
-
-
-
-
-
-
AbCellera Biologics (ABCL) PT Raised to $11 at Cantor Fitzgerald Post Q1 Print, Trial Data
-
-
-
-
-
-
-
AbCellera (ABCL) Reports FY Loss of $0.49
-
-
-
-
-
-
-
AbCellera (ABCL) Tops Q2 EPS by 2c
-
-
-
-
-
-
-
Benchmark Reiterates Hold Rating on AbCellera Biologics (ABCL)
-
-
-
-
-
-
-
Benchmark Downgrades AbCellera Biologics (ABCL) to Hold
-
-
-
-
-
-
-
AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024
-
-
-
-
-
-
-
AbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023
-
1,231,061 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


